DNAprint Genomics (DNAG)

[worktoplay]

Interesting quote in the Biofrontera PR:

Prof. Dr. Lubbert, CEO of Biofrontera AG, commented: "We are delighted to have acquired this extremely promising product in photodynamic therapy, a fairly novel treatment paradigm. The nanocolloid formulation of ALA ideally suits the dermatology focus of our leading products and combines the benefits of an already existing therapy with an innovative, in all likelihood superior formulation. Similar to our other dermatological clinical development compound, we consider the development risk of this product extremely low. This makes us very confident that we will be able to bring this new product to the market."

http://64.233.167.104/search?q=cache:gww8UtN8dswJ:news.biocompare.com/newsstory.asp%3Fid%3D53412+dna...

Later,
W2P